Edition:
United States

Profile: OncoMed Pharmaceuticals Inc (OMED.OQ)

OMED.OQ on NASDAQ Stock Exchange Global Select Market

4.47USD
22 Sep 2017
Change (% chg)

$0.06 (+1.36%)
Prev Close
$4.41
Open
$4.37
Day's High
$4.52
Day's Low
$4.37
Volume
36,697
Avg. Vol
82,839
52-wk High
$12.58
52-wk Low
$2.93

OncoMed Pharmaceuticals, Inc. (OncoMed) is a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing therapeutics that address the fundamental biology driving cancer's growth, resistance, recurrence and metastasis. The Company's therapeutic candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Navicixizumab (Anti-DLL4/VEGF Bispecific, OMP-305B83), Anti-RSPO3 (OMP-131R10), Anti-TIGIT (OMP-313M32) and GITRL-Fc trimer (OMP-336B11). Demcizumab is a humanized monoclonal antibody that inhibits Delta-like Ligand 4 (DLL4) in the Notch signaling pathway. Tarextumab is a human monoclonal antibody that binds to both the Notch2 and Notch3 receptors.

Company Address

OncoMed Pharmaceuticals Inc

800 Chesapeake Dr
REDWOOD CITY   CA   94063-4748
P: +1650.9958200
F: +1650.2988600

Company Web Links